Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibiotic spectrum coverage scoring as a potential metric for evaluating the antimicrobial stewardship team activity: a single-center study.
Oda K, Hayashi H, Yamamoto K, Kondo S, Katanoda T, Okamoto S, Miyakawa T, Iwanaga E, Nosaka K, Kawaguchi T, Nakata H. Oda K, et al. Among authors: iwanaga e. Infect Control Hosp Epidemiol. 2024 Oct 10;45(11):1-9. doi: 10.1017/ice.2024.137. Online ahead of print. Infect Control Hosp Epidemiol. 2024. PMID: 39387201 Free PMC article.
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T. Iriyama N, et al. Among authors: iwanaga e. Int J Hematol. 2024 Jul;120(1):60-70. doi: 10.1007/s12185-024-03758-4. Epub 2024 Apr 8. Int J Hematol. 2024. PMID: 38587692
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.
Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, Iriyama N, Sato E, Nakazato T, Mitsumori T, Ishikawa M, Fujita H, Kizaki M, Ando M, Hatta Y, Iwanaga E, Kawaguchi T. Tokuhira M, et al. Among authors: iwanaga e. Int J Hematol. 2023 Aug;118(2):210-220. doi: 10.1007/s12185-023-03606-x. Epub 2023 May 2. Int J Hematol. 2023. PMID: 37129800
Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
Tsuchiya S, Takaku T, Watanabe N, Iriyama N, Kimura Y, Iwanaga E, Sugimoto KJ, Mitsumori T, Ishikawa M, Nakazato T, Fujita H, Sato E, Hatta Y, Asou N, Kizaki M, Tokuhira M, Ando M, Kawaguchi T. Tsuchiya S, et al. Among authors: iwanaga e. Intern Med. 2023 Nov 15;62(22):3299-3303. doi: 10.2169/internalmedicine.1611-23. Epub 2023 Mar 31. Intern Med. 2023. PMID: 37005261 Free PMC article.
Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.
Guo M, Chan THM, Zhou Q, An O, Li Y, Song Y, Tan ZH, Ng VHE, Peramangalam PS, Tan ZQ, Cao X, Iwanaga E, Matsuoka M, Ooi MGM, Jen WY, Koh LP, Chan E, Tan LK, Goh Y, Wang W, Koh BTH, Chun CM, Fullwood MJ, Chng WJ, Osato M, Pulikkan JA, Yang H, Chen L, Tenen DG. Guo M, et al. Among authors: iwanaga e. Blood. 2023 Jun 22;141(25):3078-3090. doi: 10.1182/blood.2022015830. Blood. 2023. PMID: 36796022 Free article.
30 results